Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19

Summary

The purpose is to demonstrate the efficacy of low-dose interleukin 2 (Ld-IL2) administration in improving clinical course and oxygenation parameters in patients with SARS-CoV2-related ARDS.

Timeline

Start

2020-10-23

Primary completion

2020-11-02

Completion

2021-04-05

Publications

• Kakh M, Doroudchi M, Talepoor A. Induction of Regulatory T Cells After Virus Infection and Vaccination. Immunology. 2025 May 7. doi: 10.1111/imm.13927. Online ahead of print.

Drugs

Indications